Inmune Bio (INMB) Invested Capital (2022 - 2024)

Inmune Bio has reported Invested Capital for 3 years, with the latest figure at $2.5 million in Q3 2024.

• Quarterly Invested Capital fell 75.06% year-over-year to $2.5 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $2.5 million (down 92.31% YoY) and the FY2023 annual result came in at $10.0 million, up 100.0% from the prior year.
• Invested Capital declined to $2.5 million in Q3 2024 per INMB's latest filing, from $5.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $10.0 million in Q2 2023 and troughed at $2.5 million in Q3 2024.
• A 3-year average of $6.7 million and a median of $7.5 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2024: Invested Capital soared 300.0% in 2023, then slumped 75.06% in 2024.
• Over 3 years, Invested Capital stood at $5.0 million in 2022, then surged by 100.0% to $10.0 million in 2023, then plunged by 75.06% to $2.5 million in 2024.
• According to Business Quant data, Invested Capital over the past three periods registered $2.5 million, $5.0 million, and $7.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.